The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy)

Akouchekian, Shahla; Omranifard, Victoria; Moshfegh, Parivash; Maracy, Mohammad Reza; Almasi, Asiyeh

The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy)

Document Type : Original Article

Authors

¹ Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

³ Department of Psychiatry, Medical School, University of Medical Sciences, Isfahan, Iran

⁴ Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Considering the effect of statins on the regulation of dopamine neurotransmitters and glutamates and importance of the treatment of obsessive-compulsive disorder (OCD) due to its relatively high prevalence and disability of available drugs in treatment of many patients, we came to the point to examine effectiveness of statins in patients with OCD. Materials and Methods: This study is a double-blind randomized clinical trial, which is done in OCD clinic of Isfahan Shariati in 2014 for 1 year. The target population consists of 64 patients with OCD; one group is given a daily 40 mg atorvastatin tablets and the other group receives placebo. At baseline, 4- and 8-week severities of obsessive-compulsive symptoms are measured using Yale–Brown scale and compared in the two groups. Results: The study results show a statistically significant difference between the two groups of intervention and control (P < 0.001). Furthermore, the results show the intervention effect at the end of the 4^th week and 8^th week (P < 0.001) that this change is evident in the 4^th week but remained almost constant in the 8^th week. Conclusion: Overall, the evidences obtained from the study declare the effects of adding statins to treat obsessive-compulsive symptoms.

Keywords

References

1.	Pyati S, Gan TJ. Perioperative pain management. CNS Drugs 2007;21:185-211. [PUBMED]
2.	Gramke HF, de Rijke JM, van Kleef M, Raps F, Kessels AG, Peters ML, et al. The prevalence of postoperative pain in a cross-sectional group of patients after day-case surgery in a university hospital. Clin J Pain 2007;23:543-8. [PUBMED]
3.	Mixter CG 3^rd, Meeker LD, Gavin TJ. Preemptive pain control in patients having laparoscopic hernia repair: A comparison of ketorolac and ibuprofen. Arch Surg 1998;133:432-7.
4.	Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician 2008;11 2 Suppl: S105-20.
5.	Hopf HW, Weitz S. Postoperative pain management. Archives of Surgery. 1994 ;129(2):128-33.
6.	Sun Y, Gan TJ, Dubose JW, Habib AS. Acupuncture and related techniques for postoperative pain: A systematic review of randomized controlled trials. Br J Anaesth 2008;101:151-60.
7.	Sahmeddini MA, Farbood A, Ghafaripuor S. Electro-acupuncture for pain relief after nasal septoplasty: A randomized controlled study. J Altern Complement Med 2010;16:53-7. [PUBMED]
8.	Karaman S, Kocabas S, Zincircioglu C, Firat V. Has ketamine preemptive analgesic effect in patients undergoing abdominal hysterectomy? Agri 2006;18:36-44.
9.	Beehrle DM, Evans D. A review of NSAID complications: gastrointestinal and more. Lippincotts Prim Care Pract. 1999;3(3):305-15.
10.	Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence. J Clin Psychiatry 2004;65 Suppl 14:11-7. [PUBMED]
11.	Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: Possible implications for the involvement of D1 receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003;28:77-85. [PUBMED]
12.	Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive compulsive disorder: Serotonin and beyond. CNS Spectr 2007;12 2 Suppl 3:14-27.
13.	Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008;2:62-75. [PUBMED]
14.	Harsányi A, Csigó K, Demeter G, Németh A. New approach to obsessive-compulsive disorder: dopaminergic theories. Psychiatr Hung 2007;22:248-58.
15.	Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006;3:69-81. [PUBMED]
16.	Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction – Newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov 2007;2:47-55. [PUBMED]
17.	Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006;29:553-84, xi. [PUBMED]
18.	Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessive-compulsive disorder. CNS Spectr 2007;12 Suppl 3:S28-835.
19.	Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JR, Gorman JM, et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry 2004;161:1485-7. [PUBMED]
20.	Bland RC, Newman SC, Orn H. Age and remission of psychiatric disorders. Can J Psychiatry 1997;42:722-9. [PUBMED]
21.	Wang G, Ting WL, Yang H, Wong PT. High doses of simvastatin up-regulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: Possible involvement of endothelial nitric oxide synthase col. Br J Pharmacol 2005;144:933-9.
22.	Wang Q, Tang XN, Wang L, Yenari MA, Ying W, Goh BC, et al. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett 2006;408:189-93. [PUBMED]
23.	Wang Q, Zengin A, Deng C, Li Y, Newell KA, Yang GY, et al. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 2009;216:132-8. [PUBMED]
24.	Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: Current strategies. J Clin Psychiatry 1994;55 Suppl 3:11-7.
25.	Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol 2010;126:754-62.e1.
26.	Kudaravalli J. Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Indian J Pharmacol 2011;43:311-5. [PUBMED] [Full text]
27.	Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H. Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects. Cardiovasc Res 2006;72:438-46. [PUBMED]
28.	Tsakiri A, Kallenbach K, Fuglø D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: A randomized study. Mult Scler 2012;18:72-81.
29.	Farsaei S, Khalili H, Farboud ES. Potential role of statins on wound healing: Review of the literature. Int Wound J 2012;9:238-47. [PUBMED]
30.	Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: Is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 2007;61:412-4. [PUBMED]
31.	Hounie AG, Cappi C, Cordeiro Q, Sampaio AS, Moraes I, Rosário MC, et al. TNF-alpha polymorphisms are associated with obsessive-compulsive disorder. Neurosci Lett 2008;442:86-90.
32.	Brynska A, Wolanczyk T. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). A report of two cases. Psychiatr Pol 2004;38:105-23.
33.	Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Krönig H, et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biol Psychiatry 2005;57:667-73.
34.	Gabbay V, Coffey BJ, Guttman LE, Gottlieb L, Katz Y, Babb JS, et al. A cytokine study in children and adolescents with Tourette's disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:967-71. [PUBMED]
35.	Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000;32:164-76. [PUBMED]
36.	Lyngdoh T, Vollenweider P, Waeber G, Marques-Vidal P. Association of statins with inflammatory cytokines: A population-based Colaus study. Atherosclerosis 2011;219:253-8. [PUBMED]
37.	Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9.
38.	Kaya C, Pabuccu R, Cengiz SD, Dünder I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. Exp Clin Endocrinol Diabetes 2010;118:161-6.
39.	Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol 2010;33:222-7. [PUBMED]

Advanced Biomedical Research